Author

Jerome Paggetti

Luxembourg Institute of Health;

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alwin Huitema· 1 shared Andy ChevignéiD· 1 shared Arun K. ShuklaiD· 1 shared Ashna Reyaz· 1 shared Brian F. VolkmaniD· 1 shared Desislava Nesheva· 1 shared Dick Pluim· 1 shared Esther A. LeliveldiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alwin Huitema

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3

Maurice C.M.L. Buzink, Joy Darcis, Desislava Nesheva, Max Meyrath, Shawn Jenjak, Nilanjana Banerjee, Manisankar Ganguly, Ashna Reyaz, Ramanuj Banerjee, Esther A. Leliveld, Yong-Jun Kwon, Jerome Paggetti, Sybrand Zielhuis, Dick Pluim, Alwin Huitema, , Rob Leurs

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

bioRxiv · Nov 4, 2026 · PreprintMolecular Biology